Motley Fool Asset Management LLC Has $4.98 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Motley Fool Asset Management LLC grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 38.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,526 shares of the biopharmaceutical company’s stock after buying an additional 3,480 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $4,981,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $29,000. Ameriflex Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $32,000. Manchester Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals by 600.0% in the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 72 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $36,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $39,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 2.2%

ALNY opened at $291.22 on Thursday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $283.10 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The firm has a market capitalization of $38.88 billion, a price-to-earnings ratio of 79.57 and a beta of 0.29. The company’s 50 day moving average price is $306.05 and its two-hundred day moving average price is $345.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the firm posted ($0.44) EPS. The company’s revenue for the quarter was up 96.4% compared to the same quarter last year. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 7,740 shares of company stock worth $2,420,214 over the last three months. Insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of a number of research analyst reports. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Chardan Capital reiterated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, Truist Financial lowered their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.